A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

Status:
Recruiting

Trial end date:
2023-12-15

Target enrollment:

Participant gender:

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

Phase 1/Phase 2

NextCure, Inc.